Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of 500 mg oral BID dose of KD025 in healthy male and post-menopausal female participants.


Clinical Trial Description

Up to approximately 58 days including safety follow up period of 30 days after participant is treated with the last dose of study drug. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05918614
Study type Interventional
Source Sanofi
Contact
Status Completed
Phase Phase 1
Start date March 28, 2014
Completion date June 7, 2014